ImmunityBio Inc
IBRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.28B
Close$
$-5.63
169.2% downside
Current Fair Value
169.2% downsideOvervalued by 169.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.28 Billion |
|---|---|
| Enterprise Value | $8.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.38 |
| Beta | 0.14 |
| Outstanding Shares | 1,050,070,000 |
Return
| Return on Equity | 94.89% |
|---|---|
| Return on Assets | -157.89% |
| Return on Invested Capital | -67.92% |
Valuation & Multiples
| P/E Ratio | -8.12 |
|---|---|
| PEG | -5.46 |
| Price to Sales | - |
| Price to Book Ratio | -8.14 |
| Enterprise Value to Revenue | 49.75 |
| Enterprise Value to EBIT | -22.01 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$49.08 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$59.23 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4602▼ 34.22% |
|---|---|
| Total Calls | 17,451,200▲ 24.39% |
| Total Puts | 8,031,600▼ 28.66% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.50%▲ 2.11% |
|---|---|
| Total Invested | $1.80B▲ 31.93% |
| Investors Holding | 438▲ 20.00% |
ESG Score
No data
About ImmunityBio Inc
171 employees
CEO: Patrick Soon-Shiong NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms ...